Calidi Biotherapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CALIDI BIOTHERAPEUTICS, INC. | ||
| March 15, 2024 | By: | /s/ Allan J. Camaisa |
|---|---|---|
| Name: | Allan J. Camaisa | |
| Title: | Chief Executive Officer |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| Chief Executive Officer and Chairman of the Board | March 15, 2024 | |
| Allan J. Camaisa | (Principal Executive Officer) | |
| Chief Financial Officer | March 15, 2024 | |
| Andrew Jackson | (Principal Financial and Accounting Officer) | |
| * | Director | March 15, 2024 |
| George Ng | ||
| * | Director | March 15, 2024 |
| Alan Stewart | ||
| * | Director | March 15, 2024 |
| James Schoeneck | ||
| * | Director | March 15, 2024 |
| Scott Leftwich | ||
| * | Director | March 15, 2024 |
| David LaPre | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.